- Stock: In Stock
- Brand: Unimed Unihealth MFG. Ltd.
- Product ID: Gliclazide
100% Secure Payment
bKash | Nagad | Cards via SSLCommerz | COD
Monthly Medicines Available | Free Delivery on Eligible Orders
ADMIRA MR 30mg Tablet — Gliclazide Modified Release
Generic Name: Gliclazide 30mg (Modified Release)
Manufacturer: Beximco Pharmaceuticals Ltd.
Drug Class: Sulphonylurea — 2nd Generation (Modified Release formulation)
Dosage Form: Modified Release Tablet (MR)
Prescription Status: Prescription Only (Rx)
Mechanism of Action
Gliclazide stimulates insulin secretion from pancreatic beta cells by binding to the sulphonylurea receptor (SUR-1) on ATP-sensitive potassium (KATP) channels, causing depolarisation and calcium-mediated insulin release. The modified release (MR) formulation delivers gliclazide gradually over 24 hours, producing a more physiological, meal-linked insulin secretory profile compared to immediate-release tablets. It also has extrapancreatic effects including improvement of insulin sensitivity, reduction of platelet aggregation, and antioxidant properties particularly relevant to diabetes-related vascular complications.
Advantages of MR Formulation
- Once-daily dosing — improved patient adherence
- Smoother plasma concentration profile — lower peak-to-trough fluctuation
- Reduced risk of hypoglycaemia versus immediate-release gliclazide
- Antioxidant and antiplatelet properties — potential microvascular protection
- ADVANCE trial evidence: reduced macrovascular and microvascular events in T2DM
Indications
- Type 2 Diabetes Mellitus (T2DM) in adults — monotherapy or combination
- When lifestyle modification and metformin are insufficient
- As add-on to metformin, DPP-4 inhibitors, SGLT-2 inhibitors, or basal insulin
Dosage and Administration
| Stage | Dose | Notes |
|---|---|---|
| Starting dose | 30mg once daily | With breakfast or first main meal |
| Titration | Increase by 30mg every 4 weeks | Based on fasting blood glucose response |
| Usual maintenance | 30–90mg once daily | Most patients controlled on 60mg/day |
| Maximum dose | 120mg/day | Do not crush or chew MR tablets |
Important: Swallow whole — do not crush, chew, or split MR tablets. Take with breakfast.
Warning — Hypoglycaemia Risk
Although the MR formulation reduces hypoglycaemia risk compared to immediate-release gliclazide, it remains a sulphonylurea and can cause hypoglycaemia.
Risk factors: Skipping meals, excessive alcohol, strenuous exercise, renal/hepatic impairment, drug interactions (azoles, fibrates, NSAIDs), elderly patients.
Symptoms: Sweating, trembling, palpitations, dizziness, confusion, hunger.
Treatment: 15–20g fast-acting carbohydrate. If unconscious: IV dextrose or glucagon — emergency care needed.
Monitoring
| Parameter | Target | Frequency |
|---|---|---|
| HbA1c | <7.0% (individualise) | Every 3 months (6-monthly if stable) |
| Fasting blood glucose | 4.4–7.2 mmol/L (80–130 mg/dL) | Daily during titration |
| Renal function (eGFR) | Caution if eGFR <30 | Annually |
| Body weight | Monitor — mild weight gain possible | Each clinic visit |
Renal and Hepatic Considerations
- Mild-moderate renal impairment (eGFR 30–60): Use with caution; start at 30mg; titrate slowly
- Severe renal impairment (eGFR <30): Avoid — risk of accumulation and prolonged hypoglycaemia
- Hepatic impairment: Use with caution; insulin preferred in severe cases
Contraindications
- Type 1 Diabetes Mellitus
- Diabetic ketoacidosis (DKA)
- Severe renal or hepatic impairment
- Pregnancy and breastfeeding
- Hypersensitivity to gliclazide, other sulphonylureas, or sulphonamides
- Concomitant miconazole use
Drug Interactions
| Drug / Class | Effect |
|---|---|
| Miconazole (oral/systemic) | Contraindicated — severe hypoglycaemia |
| Fluconazole, other azoles | Increased hypoglycaemia risk — monitor closely |
| Fibrates (fenofibrate, gemfibrozil) | Potentiate glucose-lowering effect |
| NSAIDs, ACE inhibitors | May enhance hypoglycaemic effect |
| Corticosteroids, thiazide diuretics | Antagonise — raise blood glucose |
| Beta-blockers | Mask hypoglycaemia symptoms (tachycardia masked) |
| Alcohol | Unpredictable — hypoglycaemia risk; avoid |
Side Effects
| System | Side Effects |
|---|---|
| Metabolic | Hypoglycaemia (less frequent than IR gliclazide), mild weight gain |
| GI | Nausea, dyspepsia, diarrhoea, constipation (uncommon) |
| Hepatic | Elevated transaminases, cholestasis (rare) |
| Skin | Rash, pruritus, photosensitivity (rare) |
| Haematological | Anaemia, leucopenia, thrombocytopenia (very rare) |
Storage
Store below 30°C in a cool, dry place. Protect from moisture and direct sunlight. Keep out of reach of children. Do not remove from original packaging until use.
Medical Disclaimer
The information provided here is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. ADMIRA MR (Gliclazide Modified Release) must only be used under supervision of a qualified physician. Do not crush or chew modified release tablets. Regular blood glucose monitoring is essential. DiabetesStore.com.bd does not endorse self-medication. Seek immediate help in case of hypoglycaemia or adverse reactions.
